| | Study ID | Sample size (T/C) | Average age (T) | Average age (C) | Sex (M/F) | CHD duration (years) | Diagnostic criteria | Intervention (T) | Intervention (C) | Treatment duration (days) | Adverse event | Outcomes |
| | Zhang, 2005 [18] | 96/93 | 56.3 | 58.5 | T: 57/39
C: 56/37 | T: 2.4
C: 2.8 | WHO1979 | C + BSHXD | Nitrate, βRB, Aspirin | 7 | Not available | ①③ | | Zhang, 2006 [19] | 44/38 | 57.3 | 56.6 | T: 23/21
C: 21/17 | T: 3.7
C: 3.6 | DPA1998 | C + BSHXD | Nitrate, βRB, Aspirin | 90 | Not available | ①③ | | Chen and Chen, 2007 [20] | 40/40 | 61.73 ± 6.54 | 60.94 ± 6.72 | T: 24/16
C: 23/17 | T: 9.84 ± 3.43
C: 9.46 ± 3.51 | WHO1979 | C + BSHXD | Nitrate, Aspirin | 30 | Not available | ①②③ | | Guo, 2009 [21] | 30/30 | 65.5 ± 6.87 | 67.7 ± 7.32 | T: 16/14
C: 13/17 | — | WHO1979 | C + BSHXD | Aspirin, Clopidogrel | 21 | Restenosis | ①④ | | Liu, 2009 [22] | 56/54 | 47–58 | 47–58 | T: 0/56
C: 0/54 | — | WHO1979 | C + BSHXD | Nitrate, βRB, Aspirin, Statins | 180 | Not available | ①③ | | Wang, 2011 [23] | 30/30 | 57.10 ± 7.62 | 58.06 ± 8.40 | T: 14/16
C: 13/17 | — | WHO1979 | C + BSHXD | Nitrate, βRB, Aspirin, Statins | 28 | Not found | ①③④ | | Song and Shi, 2012 [24] | 25/25 | 67.36 ± 6.49 | 67.84 ± 5.28 | T: 15/10
C: 13/12 | T: 9.02 ± 10.89
C: 8.35 ± 11.25 | WHO1979 | C + BSHXD | Nitrate, βRB, Aspirin, Statins | 28 | Not available | ①④ | | Gang et al., 2014 [25] | 40/38 | 63.5 ± 6.8 | 63.0 ± 6.2 | T: 20/20
C: 20/18 | T: 5.18 ± 1.4
C: 5.7 ± 1.4 | DRA2014 | C + BSHXD | Nitrate, βRB, Aspirin, Clopidogrel, Statins | 14 | Gastrointestinal reaction | ① | | Song et al., 2015 [26] | 60/60 | 55.31 ± 8.65 | 56.63 ± 7.85 | T: 29/31
C: 32/28 | T: 1–13
C: 2–14 | CJCD2007 | C + BSHXD | Nitrate, βRB, Aspirin | 28 | Not found | ①②③ | | Wang, 2017 [27] | 36/36 | 35–75 | 35–75 | T: 20/16
C: 19/17 | — | WHO1979 | C + BSHXD | Aspirin, Clopidogrel, Statins | 21 | Not found | ①②③ |
|
|
①: total effective rate, ②: attack of angina pectoris, ③: improvement of ECG, and ④: serum biochemical indicators. BSHXD: Bushen Huoxue Decoction; CWM: conventional western medicine; T: treatment group; C: control group; M/F: men/female; CHD: coronary heart disease; WHO1979: World Health Organization Task Force on Standardization of Clinical Nomenclature; DPA1998: Department of Pharmaceutical Administration Guidelines for clinical research on cardiovascular system drugs; DRA2014: Detection and Risk Assessment of stable ischemic heart disease; CJCD2007: Chinese Journal of Cardiovascular Diseases Guidelines for the diagnosis and treatment of chronic stable angina pectoris.
|
